IDEXX Laboratories, Inc. (IDXX) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Strong FCF ⢠Premium valuation IDEXX delivers exceptional profitability and strong free cash flow but trades at rich multiples and has limited nearâterm liquidity relative to debt.
Price Behavior
Key Price Behavior Insights: ⢠Below SMA ⢠Weak momentum ⢠Support holds Support Level: $557â$558 Resistance Level: $585â$590 Price is short-term bearish: trading at $569.55 below the last-month SMA (~$585.7) with RSI ~36, near-term resistance $585â$590 and immediate support $557â$558, with small rebounds since late March that may temporarily contain downside.
Sentiment & News
Key News Insights: ⢠Diagnostics growth ⢠Institutional buying ⢠Solvency concerns IDEXX is showing durable diagnostics- and software-driven growth plus a UK cancer-test launch while institutional buying and some insider/analyst caution highlight active repositioning and balance-sheet/macroeconomic risks.
AI Summary
IDEXX has shifted from a steady high-margin consumables annuity to a capital-intensive, instrument-led platform where instrument placement cadence and consumable attach rates will now materially drive near-term revenue, margins and valuation; monitor instrument placements, attach rates, and FCF conversion as the definitive execution metrics. If placements and attach accelerate, premium multiples are warranted; if they stall or U.S. clinic visits weaken, expect outsized multiple compression and pressure on buybacks.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |